Fragility fractures in France: epidemiology, characteristics and quality of life (the EPIFRACT study)

Abstract

Summary

Between 1 and 2% of people aged 50 years and over living at home in France are likely to experience a fragility fracture each year. Three-quarters of these individuals are not diagnosed with osteoporosis and lose the opportunity for appropriate care.

Purpose

To estimate the incidence of fragility fractures in France and to describe the characteristics of individuals with such fractures and of their fractures.

Methods

In April–May 2018, a postal survey was performed in France targeting a representative panel of 15,000 individuals aged ≥ 50 years, who were invited to complete a questionnaire. If they reported experiencing a fracture in the previous 3 years, they were asked to provide information on demographics, fracture type, risk factors for fractures and osteoporosis diagnosis. Only fragility fractures were considered, and these were classified as major (associated with increased mortality) or minor, based on the fracture site.

Results

Around 13,914 panellists returned an exploitable questionnaire (92.8%). About 425 participants reported ≥ 1 fragility fracture (453 fractures), corresponding to a 12-month incidence rate of 1.4% [95%CI: 1.2, 1.6]. Incidence was higher in women (1.99% [1.87, 2.05]) than in men (0.69% [0.38, 0.86]) and increased with age. Around 157 fractures (34.6%) were classified as major. Participants reporting major fractures were older than those reporting minor fractures (mean age: 72.6 ± 11.3 vs 67.1 ± 10.6) and more likely to report previous corticosteroid use (odds ratio: 1.90 [95%CI: 1.13, 3.18]). No other patient characteristic was associated with fracture severity. About 117 participants with fractures (27.5%) had undergone bone densitometry, and 97 (22.8%) declared having received a diagnosis of osteoporosis.

Conclusions

Around 340,000 people aged ≥ 50 years living at home in France are estimated to experience osteoporotic fractures each year. However, > 75% of panellists reporting fractures were never diagnosed with osteoporosis and thus did not have the opportunity to receive appropriate care.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig.3

References

  1. 1.

    Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S (2016) Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop 7(3):171–181. https://doi.org/10.5312/wjo.v7.i3.171

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    International Osteoporosis Foundation (2018) Broken bones, broken lives: the fragility fracture crisis in six European countries. http://share.iofbonehealth.org/EU-6-Material/Reports/IOF%20Report_EU.pdf

  4. 4.

    Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 16:158. https://doi.org/10.1186/s12877-016-0332-0

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Al-Sari UA, Tobias J, Clark E (2016) Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. Osteoporos Int 27(10):2891–2900. https://doi.org/10.1007/s00198-016-3648-x

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Martin AR, Sornay-Rendu E, Chandler JM, Duboeuf F, Girman CJ, Delmas PD (2002) The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 31(1):32–36

    CAS  Article  Google Scholar 

  7. 7.

    Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301(5):513–521. https://doi.org/10.1001/jama.2009.50

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Breart G (1996) Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 348(9021):145–149

    CAS  Article  Google Scholar 

  9. 9.

    Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32(1):78–85

    CAS  Article  Google Scholar 

  10. 10.

    Maravic M, Le Bihan C, Landais P, Fardellone P (2005) Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int 16(12):1475–1480

    Article  Google Scholar 

  11. 11.

    Haute Autorité de Santé (2003) Prévention, diagnostic et traitement de l’ostéoporose

  12. 12.

    International Osteoporosis Foundation (2018) Os brisés, vies brisés: une feuille de route pour résoudre la crise des fractures de fragilité en France. http://share.iofbonehealth.org/EU-6-Material/Reports/IOF%20Report_EU.pdf

  13. 13.

    Charles MA, Eschwege E, Basdevant A (2008) Monitoring the obesity epidemic in France: the Obepi surveys 1997-2006. Obesity (Silver Spring, Md) 16(9):2182–2186. https://doi.org/10.1038/oby.2008.285

    Article  Google Scholar 

  14. 14.

    Reach G, Pellan M, Crine A, Touboul C, Ciocca A, Djoudi Y (2018) Holistic psychosocial determinants of adherence to medication in people with type 2 diabetes. Diabetes Metab 44(6):500–507. https://doi.org/10.1016/j.diabet.2018.06.001

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Mosnier-Pudar H, Hochberg G, Eschwege E, Halimi S, Virally ML, Guillausseau PJ, Touboul C, Dejager S (2010) How patients’ attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS survey. Diabetes Metab 36(6 Pt 1):476–483. https://doi.org/10.1016/j.diabet.2010.08.004

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    EuroQol – a new facility for the measurement of health-related quality of life (1990). Health policy (Amsterdam) 16 (3):199–208

  17. 17.

    Devlin NJ, Brooks R (2017) EQ-5D and the EuroQol group: past, present and future. Applied health economics and health policy 15(2):127–137. https://doi.org/10.1007/s40258-017-0310-5

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5):708–715. https://doi.org/10.1016/j.jval.2012.02.008

    Article  PubMed  Google Scholar 

  19. 19.

    Institut National de la Statistique et des Etudes Economiques (2018) Bilan démographique:2017

  20. 20.

    Deville J-C, Sarndal C-E, Sautory O (1993) Generalized raking procedures in survey sampling. J Am Stat Assoc 88(423):1013–1020

    Article  Google Scholar 

  21. 21.

    Oberlin P, Mouquet M-C (2016) Quel risque de décès un an après une fracture du col du fémur ? Etudes et Résultats 0948:1–6

    Google Scholar 

  22. 22.

    Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. Jama 297(4):387–394. https://doi.org/10.1001/jama.297.4.387

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Thélot B, Lasbeur L, Pédrono G (2017) La surveillance épidémiologique des chutes chez les personnes âgées. Bull Epidemiol Hebd 16-17:328–335

    Google Scholar 

  24. 24.

    Bringer J, Fontaine P, Detournay B, Nachit-Ouinekh F, Brami G, Eschwege E (2009) Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study. Diabetes Metab 35(1):25–31. https://doi.org/10.1016/j.diabet.2008.06.004

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Fagot-Campagna A, Romon I, Fosse S, Roudie C (2010) Prévalence et incidence du diabète, et mortalité liée au diabète en France – Synthèse épidémiologique. Institut de veille sanitaire, St Maurice

    Google Scholar 

  26. 26.

    Lepine JP, Gasquet I, Kovess V, Arbabzadeh-Bouchez S, Negre-Pages L, Nachbaur G, Gaudin AF (2005) Prevalence and comorbidity of psychiatric disorders in the French general population. L'Encephale 31(2):182–194

    Article  Google Scholar 

  27. 27.

    Bénard E, Detournay B, Neukirch F, Pribil C, El Hasnaoui A (2005) Prévalence de la bronchopneumopathie chronique obstructive (BPCO) : estimation pour la France. Lett Pneumol 8(4):158–163

    Google Scholar 

  28. 28.

    Perrine AL, Lecoffre C, Blacher J, Olié V (2018) L’hypertension artérielle en France : prévalence, traitement et contrôle en 2015 et évolutions depuis 2006. Bull Epidémiol Hebd 10:170–179

    Google Scholar 

  29. 29.

    Delmas MC, Leynaert B, Com-Ruelle L, Annesi-Maesano I, Fuhrman C (2008) Asthme : prévalence et impact sur la vie quotidienne. Analyse des données de l’enquête décennale santé 2003 de l’Insee. Institut National de veille sanitaire, St Maurice

    Google Scholar 

  30. 30.

    Briot K (2018) Bone and glucocorticoids. Ann Endocrinol 79(3):115–118. https://doi.org/10.1016/j.ando.2018.04.016

    Article  Google Scholar 

  31. 31.

    Roux C, Fardellone P, Lespessailles E, Cotte FE, Mercier F, Gaudin AF (2008) Prevalence of risk factors for referring post-menopausal women for bone densitometry. The INSTANT study. Joint Bone Spine 75(6):702–707

    Article  Google Scholar 

  32. 32.

    Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Levi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Artus PM, Vieillard MH, Debiais F (2018) French recommendations for osteoporosis prevention and treatment in patients with prostate Cancer treated by androgen deprivation. Joint Bone Spine. https://doi.org/10.1016/j.jbspin.2018.09.017

  33. 33.

    Haute Autorité de Santé (2006) Ostéodensitométrie [absorbimétrie osseuse] sur 2 sites par methode biphotonique. HAS, Paris

    Google Scholar 

  34. 34.

    Coretti S, Ruggeri M, McNamee P (2014) The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res 14(2):221–233. https://doi.org/10.1586/14737167.2014.894462

    Article  PubMed  Google Scholar 

  35. 35.

    Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uuskula A, Tosteson ANA, Jonsson B, Kanis JA (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29(3):557–566. https://doi.org/10.1007/s00198-017-4317-4

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Svedbom A, Borgstrom F, Hernlund E, Strom O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Uuskula A, Lember M, Kallikorm R, Lesnyak O, McCloskey E, Ershova O, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson ANA, Jonsson B, Kanis JA (2018) Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Qual Life Res 27(3):707–716. https://doi.org/10.1007/s11136-017-1748-5

    Article  PubMed  Google Scholar 

Download references

Funding

The study was jointly conducted and funded by the AFLAR, Amgen and UCB Pharma S.A., France, who initiated the study and supervised its implementation and the exploitation of the findings, including the preparation of this manuscript. Editorial support was provided by Foxymed, funded by UCB Pharma S.A.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Bernard Cortet.

Ethics declarations

Conflict of interest

JMJ and BV are employees of UCB Pharma S.A., France. BC has received consultancy honoraria of speaker’s fees from Amgen, Expanscience, Ferring, Lilly, Medtronic, MSD, Novartis, Roche diagnostics, Théramex and UCB Pharma S.A. JMF has received consultancy honoraria and conference fees from UCB Pharma S.A., Amgen and Lilly. LG has received honoraria from Amgen, Lilly and UCB Pharma S.A. and research support from Lilly, Amgen, UCB Pharma, Expanscience, Mylan, Roche diagnostics and TEVA. KB has received consultancy honoraria and conference fees from UCB Pharma S.A., Amgen, Lilly and MSD. No other authors report conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 22 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cortet, B., Chauvin, P., Feron, JM. et al. Fragility fractures in France: epidemiology, characteristics and quality of life (the EPIFRACT study). Arch Osteoporos 15, 46 (2020). https://doi.org/10.1007/s11657-019-0674-2

Download citation

Keywords

  • Fracture
  • Osteoporosis
  • Falls
  • Diagnosis
  • Risk factors
  • France